Structure Therapeutics is trading 4.1% up at $50.32 as biotech shares continue to rally amid a broader risk-on environment.
- The sector backdrop remains supportive, with the XBI up 2.02% and broader U.S. equities trading sharply higher.
- No clear company-specific catalyst has emerged, suggesting the move is tracking the stronger tone across growth and biotech names rather than a Structure Therapeutics announcement.